findmyKOL
Clinical trialNCT04212013Active, not recruitingPhase 3Interventional

A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma

SponsorMemorial Sloan Kettering Cancer CenterEnrollment23Marginal Zone Lymphoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to see if the combination of rituximab and ibrutinib can help people with marginal zone lymphoma who have not received treatment in the past. The study will also compare the combination of rituximab and ibrutinib with the combination of rituximab and placebo to see which combination works better.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • George Washington Cancer Center

    Washington D.C., District of Columbia, United States

  • Moffitt Cancer Center

    Tampa, Florida, United States

  • Mayo Clinic Cancer Center

    Rochester, Minnesota, United States

  • Memorial Sloan Kettering Basking Ridge

    Basking Ridge, New Jersey, United States

  • Memorial Sloan Kettering Monmouth

    Middletown, New Jersey, United States

  • Memorial Sloan Kettering Bergen

    Montvale, New Jersey, United States

  • Memorial Sloan Kettering Commack

    Commack, New York, United States

  • Memorial Sloan Kettering Westchester

    Harrison, New York, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, United States

  • Memorial Sloan Kettering Nassau

    Uniondale, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ibrutinib →Rituximab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
23 Dec 2019
Primary completion
18 Mar 2027
Completion
18 Mar 2027
Last update posted
23 Jul 2026
Registered enrollment
23
Registry id
NCT04212013
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.